Braskem vs Methanex
BAK and MEOH side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BAK and MEOH compare
Methanex grew revenue faster over the last twelve months (−3.5% versus −8.6% for Braskem).
Methanex scores higher on the StockData Score (4 against 0 for Braskem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BAK | MEOH |
|---|---|---|
| Size and price | ||
| Share price | $1.13 | $70.51 |
| Change, 1 year | −62.2% | 82.6% |
| Change, 5 years | −93.3% | 63.3% |
| Beta (5Y) | 0.74 | 0.71 |
| Employees | 1,809 | – |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 3 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −8.6% | −3.5% (better) |
| Revenue growth, 5Y average | 3.9% | 6.3% (better) |
| EPS growth (TTM) | – | −61.1% |
| Profitability | ||
| Gross margin | 2.2% | 35.7% (better) |
| Operating margin | −2.6% | 12.0% (better) |
| Net margin | −14.0% | – |
| FCF margin | −10.3% | 25.5% (better) |
| Return on invested capital | −4.4% | 7.3% (better) |
| Financial health | ||
| Debt / equity | – | 1.13 |
| Net debt / EBITDA | 12.16 | 2.65 (better) |
| Interest coverage | −0.3× | 2.0× (better) |
| Current ratio | 0.76 | 2.06 (better) |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Years of dividend growth | – | 1 |
| Dividend growth, 5Y average | – | 9.4% |
| Ownership | ||
| Held by institutions | 4.1% | 76.2% |
| Held by insiders | 3.2% | 15.3% |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 3.7% |
Go deeper
- BAK stock overview
- BAK income statement
- BAK valuation and score
- MEOH stock overview
- MEOH income statement
- MEOH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.